Tempus AI has acquired OneOme for an undisclosed amount, bringing together a prominent healthcare technology company focused on artificial intelligence and data with a leader in precision medicine and pharmacogenomics. OneOme, based in Minneapolis, Minnesota, provides evidence-based pharmacogenomic solutions designed to facilitate more personalized prescriptions across the globe.
OneOme is known for its RightMed solution, which helps healthcare organizations, providers, and payers optimize patient outcomes and reduce costs by offering insights into how a patient's DNA may affect their response to medications. The company operates an in-house CLIA-certified and CAP-accredited lab, providing powerful genetic insights through its RightMed test and associated healthcare technology and analytics products. Its mission centers on delivering cost-effective, comprehensive, personalized pharmacogenomics analysis integrated into everyday clinical care.
This acquisition is strategically significant for Tempus AI, enhancing its capabilities in personalized medicine by integrating OneOme's specialized pharmacogenomic data and solutions into its broader AI-driven healthcare platform. The move is expected to create synergies that will accelerate the development and adoption of data-informed medication decisions, providing a more holistic view of patient health for clinicians. By combining Tempus AI's advanced analytical tools with OneOme's genetic insights, the unified entity aims to improve drug efficacy, minimize adverse drug reactions, and contribute to overall healthcare cost reduction.
The integration of OneOme's offerings into Tempus AI is anticipated to further advance precision medicine, offering healthcare professionals enhanced resources for tailoring treatment plans. This strategic purchase underscores a commitment to leveraging genetic data to optimize patient care on a wider scale.